Is It Over for This Huntington’s Disease Clinical Trial?

By Chris Lange Published Dec 30, 1:10PM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Is It Over for This Huntington’s Disease Clinical Trial? — © stevecoleimages / Getty Images

Wave Life Sciences Ltd. (NASDAQ: WVE) shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.

Specifically, the results come from the firm’s Phase 1b/2a Precision-HD2 trial evaluating investigational therapy WVE-120102, designed to be the first allele-selective approach to treat Huntington’s disease.

In an analysis comparing all patients treated with multiple doses of WVE-120102 to placebo, a statistically significant reduction of 12.4% in mutant huntingtin (mHTT) protein was observed in cerebrospinal fluid. An analysis to assess a dose response across treatment groups suggested a statistically significant response in mHTT reduction at the highest doses tested.

While there was a statistically significant reduction in mHTT with WVE-120102 compared to the placebo in the topline analysis, there was no difference in total HTT compared to placebo, suggesting WVE-120102 may have a potentially differential effect on huntingtin as measured by the mHTT and the total HTT assays.

Overall, WVE-120102 was generally safe and well tolerated across all cohorts. These data support the addition of higher dose cohorts, and Wave expects to initiate a 32 mg cohort in January 2020.

[nativounit]

Michael Panzara, M.D., MPH, chief medical officer of Wave Life Sciences, commented:

This topline analysis has given us the opportunity to evaluate early data from our ongoing dose finding study. The data demonstrate a reduction in mutant HTT and a safety and tolerability profile that supports exploration of higher doses of WVE-120102, with the goal of maximizing mutant HTT reduction and avoiding a negative impact on the healthy huntingtin protein. We plan to initiate the 32 mg cohort imminently and look forward to sharing data in the second half of 2020.

Shares of Wave Life Sciences were last seen down 49% at $8.06, in a 52-week range of $14.39 to $48.64. The consensus price target is $33.29.

[recirclink id=600892]
[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.